A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
Clinical trial NCT03497767 · COMPLETED
Trial details
- NCT number
- NCT03497767
- Sponsor
- Trans Tasman Radiation Oncology Group
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-15
- Primary completion
- 2024-04-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.